A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.

Abstract

Two hundred and forty-two patients with acute schizophrenia were enrolled in a double-blind, comparative, dose-finding study of a novel antipsychotic, remoxipride. Remoxipride was evaluated in a low (30 to 90 mg), medium (120 to 240 mg) and a high (300 to 600 mg) dose range and compared with a haloperidol (15 to 45 mg), which was administered to a similar group of patients. The results support the antipsychotic effect of remoxipride, with maximum efficacy occurring at daily doses between 120 mg and 600 mg. Side-effects were more frequent at doses of remoxipride over 300 mg. In all groups, remoxipride caused consistently fewer extrapyramidal side-effects than haloperidol. The antipsychotic effect of remoxipride may be derived from specific blockade of dopamine D2 receptors in the mesolimbic tract. The findings also suggest that remoxipride may have a therapeutic effect on negative symptoms of schizophrenia.

• Authors: Y D Lapierre, R Ancill, G Awad, D Bakish, P Beaudry, D Bloom, R Chandrasena, M Das, C Durand, D Elliott
• Journal: Journal of psychiatry & neuroscience : JPN (J Psychiatry Neurosci) Vol. 17 Issue 4 Pg. 134-45 (Oct 1992) ISSN: 1180-4882 [Print] Canada
• PMID: 1450186 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Remoxipride
• Haloperidol

Topics

• Dose-Response Relationship, Drug
• Double-Blind Method
• Dyskinesia, Drug-Induced (etiology)
• Haloperidol (administration & dosage, adverse effects)
• Humans
• Psychiatric Status Rating Scales
• Recurrence
• Remoxipride (administration & dosage, adverse effects)
• Schizophrenia (drug therapy)
• Schizophrenic Psychology